B+
Bull case
20%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
PCRX
Pacira BiosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The commercial EXPAREL franchise may continue gaining share, while PCRX-201 manufacturing readiness, ASCENT progress, and the Zimmer Biomet partnership provide potential longer-term optionality.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +5.4.
What can break
Commercial upside depends on sustained access expansion and outpatient uptake.
Momentum
37
Value
69
Sentiment
55
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $30.00 · Bear $18.00Analysis 2026-08-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $29.75
Why
Momentum37 · Δ7d -20.4
Value69 · Δ7d -0.0
Sentiment55 · Δ7d +5.4
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +5.4.
Contradictions & invalidation
- • Commercial upside depends on sustained access expansion and outpatient uptake.
- • Macroeconomic softness in elective procedures could pressure EXPAREL demand.
- • Elective-procedure softness, execution risk around PCRX-201 development, and limited evidence of analyst estimate or target revisions constrain conviction.
Catalyst clock
2026-08-04
Q2 2026 earnings follow-up
Lead driver: Sentiment · See AI snapshot
Momentum
37
9% active weight
Current posture
7d trendSoftening
Δ7d
-20.4
Δ21d
+5.7
Value
69
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.8
Sentiment
55
62% active weight
Current posture
7d trendImproving
Δ7d
+5.4
Δ21d
-7.8
Why this grade
Composite grade C. Momentum 37.1 / Value 68.7 / Sentiment 55.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-17. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$926.39M
Beta
0.25
Shares Out
39.86M
P/E (TTM)
53.8
P/S (TTM)
1.51
P/FCF (TTM)
8.69
Rev YoY
+6.2%
EPS YoY
-208.3%
Gross Margin
+71.5%
Op Margin
+3.7%
Net Debt
$179.78M
Current Ratio
5.04
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data